Surgical management of metastatic peritoneal or pleural disease.
The surgeon's role in the treatment of malignant peritoneal disease has expanded over time, stemming from a better understanding of tumor biology. For the majority of patients, carcinomatosis is a terminal process with surgical intervention being reserved for palliation of bowel obstruction or symptomatic ascites. However, for select patients with favorable tumor biologies, aggressive surgical approaches may result in long-term survival. This review describes the patterns of peritoneal tumor dissemination, surgical palliation of malignant bowel obstruction or ascites, and the principles, indications, toxicities, and overall results of cytoreductive surgery with intraperitoneal hyperthermic chemotherapy. On the other hand, long-term survival is rarely expected for malignant pleural disease unless the causal tumor is highly responsive to systemic chemotherapy. There are controversies and considerable geographic variations in the management of malignant pleural effusions. However, less invasive ambulatory palliative treatments for patients so afflicted are gaining popularity.
Gushchin
Vadim
V
Institute for Cancer Care at Mercy, Baltimore, MD, USA.
Demmy
Todd L
TL
Kane
John M
JM
D001201:Ascites / Q000209:etiology / Q000601:surgery; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects; D003131:Combined Modality Therapy; D004322:Drainage / Q000379:methods; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology / Q000601:surgery; D010166:Palliative Care; D010534:Peritoneal Neoplasms / Q000150:complications / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D010996:Pleural Effusion / Q000209:etiology / Q000628:therapy; D010997:Pleural Neoplasms / Q000150:complications / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D011379:Prognosis; D015911:Sclerotherapy / Q000379:methods